According to a recent LinkedIn post from Okami Medical, the company plans to feature its LOBO HDBRAID peripheral embolization device at the GEST 2026 conference in New York. The post describes LOBO as designed for fast and complete occlusion and positions it as suitable for single-device occlusions across a range of peripheral cases.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post also notes that Okami Medical will host a hands-on workshop on coils and plugs, as well as a masterclass on plugs and stent grafts, during the event. This emphasis on live demonstrations and education may help drive physician adoption, potentially supporting longer-term procedure volumes and product pull-through if the device gains traction among interventional radiologists.
For investors, the focus on conference-based exposure suggests that Okami Medical is prioritizing clinical engagement and real-world use cases over broad consumer-style promotion. Strong visibility at a specialized meeting like GEST could enhance the company’s positioning in the vascular occlusion segment and may contribute to competitive differentiation against established embolization technologies.